The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+

    Dr Reddy’s receives DCGI’s approval to conduct clinical trial for Sputnik V vaccine in India

    Synopsis

    In September 2020, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.

    Agencies
    In September 2020, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine.
    Dr Reddy's has received the permission from the Drug Controller General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for the Sputnik V vaccine in India. This is the vaccine developed by the Russia's Gamaleya Institute and funded by Russian Development Investment Fund (RDIF). The multi-center and randomized controlled study, which will include safety and immunogenicity study.

    In September 2020, Dr. Reddy’s and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.

    Sputnik V is currently undergoing phase 3 clinical trial in Russia and the proposed number of subjects is 40,000. Additionally, phase 3 clinical trial of the vaccine has commenced in the UAE last week.

    This is a significant development that allows us to commence the clinical trial in India and we are committed to bringing in a safe and efficacious vaccine to combat the pandemic, said G V Prasad, Managing Director, Dr. Reddy’s Laboratories in a press statement.

    (Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    Also Read

    3 Comments on this Story

    srinivas12 days ago
    Top priority should be to vaccinate across group of states in line with established distribution networks of both civil & defence.
    RajeshK12 days ago
    The Most Important Thing:
    https://amzn.to/353i6sl
    Yash Pal12 days ago
    This is good news. Hope the trials succeed. 5 crore people can be vaccinated if 100 million doses are made immediately after approval. Hopefully, the Russian vaccine will be affordable.
    The Economic Times